On April 30, 2024 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that Roche issued an Investor Update regarding anti-cancer agent/ALK inhibitor Alecensa (alectinib). The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended to approve Alecensa monotherapy as adjuvant treatment following complete tumor resection for adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer at high risk of recurrence (Press release, Chugai, APR 30, 2024, View Source;category= [SID1234642443]).
*Stage IB (tumours ≥ 4 cm) – IIIA non-small cell lung cancer (UICC/AJCC 7th edition)

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Please refer to the link below for details of the Investor Update:

CHMP recommends EU approval of Roche’s Alecensa as the first adjuvant treatment for resected ALK-positive early-stage lung cancer
View Source